Company Overview: ALNY

Upcoming Projects (ALNY)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ALNY)

A Second Opinion: Discussing the Topline Results from Alnylam's APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Ticker: ALNY
Executed On: Aug 10, 2022 at 03:00 PM EDT
Discussing the Topline Results from Alnylam's APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Ticker: ALNY
Executed On: Aug 09, 2022 at 03:00 PM EDT
A look at patisiran ahead of the APOLLO-B readout
Ticker: ALNY
Executed On: May 31, 2022 at 03:00 PM EDT
Examining Alnylam's pipeline in treating cardiac amyloidosis
Ticker: ALNY
Executed On: Mar 24, 2022 at 02:00 PM EDT

Expired Projects (ALNY)

Digging into Alnylam’s recently presented additional results from APOLLO-B Phase 3 study of patisiran in ATTR
Ticker: ALNY
Execute By: Nov 30, 2022
Digging into Alnylam’s recently approved Oxlumo in primary hyperoxaluria
Ticker: ALNY
Execute By: Nov 30, 2022
Discussing Alnylam’s Lumasiran in primary hyperoxaluria type 1
Ticker: ALNY
Execute By: Jun 30, 2022
A look at Alnylam’s Vutrisiran in treating hATTR Amyloidosis potential market share and potential, with recent P3 data to discuss
Ticker: ALNY
Execute By: Apr 29, 2022

Upcoming & Overdue Catalysts (ALNY)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ALNY)

Alnylam (ALNY) Initiates APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Ticker: ALNY
Occurred on: Sep 16, 2019
Silence Therapeutics (SLN) Sues Alnylam (ALNY) on dispute over commercialization of ONPATTRO (patisiran) in the EU
Tickers: ALNY, IONS, SLN.L, AKCA
Occurred on: Oct 11, 2018
NDA of Patisiran for Familial Amyloidotic Polyneuropathy in patients with ATTR to be filed late 2017, assuming positive data
Ticker: ALNY
Occurred on: Nov 16, 2017
Phase 3 data due of Patisiran APOLLO trial for Familial Amyloidotic Polyneuropathy in Patients with ATTR due in Mid-2017
Ticker: ALNY
Occurred on: Sep 20, 2017
Initiation of two Phase 3 trials for Fitusiran (ALN-AT3), in treating severe hemophilia A and B patients with and without inhibitors is expected in early 2017
Ticker: ALNY
Occurred on: Sep 07, 2017
Alnylam (ALNY) Expects to Initiate Phase 3 Trial in Late 2017 Study Evaluating Givosiran (ALN-AS1) for the Treatment of Acute Hepatic Porphyrias
Ticker: ALNY
Occurred on: Sep 07, 2017
Start of Phase 3 Givosiran study expected in late 2017
Ticker: ALNY
Occurred on: Sep 07, 2017
New, One-Year Data from ORION-1 Phase II Study of Inclisiran Affirms Dose for Phase III Trials
Ticker: ALNY
Occurred on: Aug 28, 2017
Givosiran Additional data release from Phase 1 anticipated in mid-2017
Ticker: ALNY
Occurred on: Jun 26, 2017
Phase 3 Studies of Inclisiran for Hypercholesterolemia Expected to Start in the First Half of 2017
Ticker: ALNY
Occurred on: Apr 26, 2017
Phase 2 36-month OLE data of Patisiran in hATTR Patients with Polyneuropathy expected in late 2017
Ticker: ALNY
Occurred on: Apr 26, 2017
BPC of Patisiran estimate mid 2017 for data release
Ticker: ALNY
Occurred on: Apr 26, 2017
Alnylam Presents New Data on Fitusiran at EAHAD
Ticker: ALNY
Occurred on: Feb 02, 2017
Alnylam to File an IND for ALN-HBV in early 2016
Ticker: ALNY
Occurred on: Jan 09, 2017
Phase 2 data of Inclisiran for Hypercholesterolemia Expected in early 2017
Ticker: ALNY
Occurred on: Jan 08, 2017
If the Phase 1/2 study results of ALN-CC5 are positive, Alnylam expects to initiate a Phase 3 trial in 2017
Ticker: ALNY
Occurred on: Dec 05, 2016
Fitusiran (ALN-AT3) Phase 1 Open Label Extension study initial data expected in late 2016
Ticker: ALNY
Occurred on: Dec 03, 2016
Initial data from the ORION-1 Phase 2 study on ALN-PCSsc are expected to be presented by The Medicines Company (MDCO) on November 15, 2016
Tickers: ALNY, MDCO
Occurred on: Nov 15, 2016
The Medicines Company (MDCO) and Alnylam Pharma (ALNY) Announce Phase 1 Data Evaluating Hypercholesterolemia Treatment Inclisiran (ALN-PCSsc) in The New England Journal of Medicine (NEJM)
Tickers: ALNY, MDCO
Occurred on: Nov 13, 2016
Alnylam (ALNY) Announces Data Monitoring Committee Recommends Continuation of Phase 3 APOLLO Study Evaluating Patisiran in Hereditary ATTR Amyloidosis
Ticker: ALNY
Occurred on: Oct 10, 2016
Phase 3 data of Revusiran ENDEAVOUR trial for ATTR in patients with familial amyloidotic cardiomyopathy (FAC) due 2018
Ticker: ALNY
Occurred on: Oct 05, 2016
Initial Phase 1 clinical data for ALN-AAT in treating of AAT deficiency-associated liver disease to be presented at 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
Ticker: ALNY
Occurred on: Sep 28, 2016
Initial Phase 1 clinical data for ALN-GO1 in treating Primary Hyperoxaluria Type 1 will be presented in late 2016
Ticker: ALNY
Occurred on: Sep 24, 2016
Data from the ongoing Phase 1 study of ALN-AS1 for the treatment of acute hepatic porphyrias, including initial data in patients that experience recurring porphyria attacks - in late 2016.
Ticker: ALNY
Occurred on: Sep 07, 2016
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in Phase 1 Clinical Study
Ticker: ALNY
Occurred on: Aug 30, 2016
Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM)
Ticker: ALNY
Occurred on: Aug 08, 2016
Fitusiran (ALN-AT3) for the treatment of hemophilia and rare bleeding disorders (RBD) Present additional data from the ongoing Phase 1 trial in mid-2016.
Ticker: ALNY
Occurred on: Jul 25, 2016
Alnylam to start a Phase 1 trial in mid-2016 for ALN-HBV, an investigational RNAi therapeutic targeting the hepatitis B viral (HBV) genome for the treatment of chronic HBV infection
Ticker: ALNY
Occurred on: Jul 07, 2016
Alnylam Initiated Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5; expects to report initial PNH patient data from this ongoing clinical study in mid-2016
Ticker: ALNY
Occurred on: Jun 11, 2016
Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
Ticker: ALNY
Occurred on: Apr 20, 2016
Alnylam Filed a Clinical Trial Application (CTA)with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for ALN-GO1; plans to initiate a Phase 1 study with ALN-GO1 in early 2016
Ticker: ALNY
Occurred on: Mar 09, 2016
Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin-Mediated Amyloidosis
Ticker: ALNY
Occurred on: Feb 01, 2016
24-month data from the Phase 2 Open-Label Extension (OLE) study with patisiran to be released in mid-2016
Ticker: ALNY
Occurred on: Jan 11, 2016

Strategic Initiatives (ALNY)

Regeneron (REGN) and Alnylam (ALNY) Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Tickers: REGN, ALNY
Announcement Date: Apr 08, 2019
Sanofi (SNY) and Alnylam (ALNY) Agree to Co-Develop and Commercialize RNAi Therapeutic Fitusiran in Treatment of Hemophilia and Rare Bleeding Disorders
Tickers: ALNY, SNY
Announcement Date: Nov 14, 2016

ALNY Overview